Denali Therapeutics (DNLI) Long-Term Deferred Tax (2018)

Denali Therapeutics' (DNLI) quarterly Long-Term Deferred Tax came in at $23.5 million in Q1 2018.

Denali Therapeutics (DNLI) Long-Term Deferred Tax (2018) Analysis & Trends

Denali Therapeutics (DNLI) has 1 years of Long-Term Deferred Tax data on file, last reported at $23.5 million in Q1 2018.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	67,072.09 Bn	67,072.09 Bn	-
2	Nanobiotix	1,894.61 Bn	1,894.55 Bn	-
3	Akari Therapeutics	1,014.18 Bn	1,014.18 Bn	-
4	BeOne Medicines	471.64 Bn	466.85 Bn	1.35 Bn
5	Vertex Pharmaceuticals	121.72 Bn	114.47 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	68.28 Bn	59.52 Bn	3.31 Bn
7	Belite Bio	61.40 Bn	61.40 Bn	-
8	Argenx Se	56.94 Bn	56.94 Bn	1.18 Bn
9	Revolution Medicines	37.37 Bn	37.37 Bn	-
10	Denali Therapeutics	4.33 Bn	4.33 Bn	-

Download Data

Date	Value
Mar 31, 2018	23.50 Mn